SCHEMBL4911059

SCHEMBL4911059

NC(CC(=O)N1CCC(Sc2ccccn2)CC1)(C(=O)O)c1ccc(Cl)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
ALDH1A1 P00352 4/20 0.41
LMNA P02545 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
EPHX2 P34913 4/20 0.38
GRM5 P41594 3/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.36
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CYP2J2 P51589 1/20 0.35
FNTA P49354 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4795360 0.73 HDAC8 (0.56) EPHX2
SCHEMBL4902706 0.73 HDAC8 (0.56) EPHX2
SCHEMBL5269510 0.71 POLB (0.48) POLBALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL4911051 0.71 MC4R (0.46) EPHX2CYP2C9CYP2C19CYP2J2
SCHEMBL4768721 0.66 GPR119 (0.62) POLBKDM4EGRM5
SCHEMBL10668947 0.66 GAA (0.56) ALDH1A1SMN1; SMN2HPGDGAANPC1
SCHEMBL8708817 0.63 EHMT2 (0.42) POLBALDH1A1LMNASMN1; SMN2MAPT
SCHEMBL14535814 0.63 NPC1 (0.52) LMNASMN1; SMN2HPGDNPC1RAB9A
SCHEMBL5265933 0.62 DDB1 (0.44) MAPTGRM5
SCHEMBL10640635 0.61 EHMT2 (0.54) POLBALDH1A1LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof NOVARTIS AG 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255149-A1 Carboxyamine Compounds and Methods of Use Thereof HNMT, HDAC5, HDAC4 POLB 2307/4885ALDH1A1 1068/4885LMNA 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.